Arbekacin sulfate concentrations in peripheral lymph and in serum after intravenous injection: Report of four cases

Japanese Journal of Antibiotics

Volumn 65, Issue 3, 2012, Pages 207-215

  Hayashi, Masahiko ^a,b   Ooi, Kazuya ^b   Yamada, Satoko ^a   Wakabayashi, Hiromi ^a   Imanishi, Takao ^a   Kondo, Makoto ^a   Nishii, Masami ^a   Ikawa, Kazuro ^c   Morikawa, Norifumi ^c  

^a Ise General Municipal Hospital   (Japan)

^b SUZUKA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HABEKACIN;

ADULT; AGED; ARTICLE; BOLUS INJECTION; CASE REPORT; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG LYMPH LEVEL; HUMAN; INFUSION RATE; SKIN INFECTION; SOFT TISSUE INFECTION;

AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; DIBEKACIN; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; LYMPH; MALE; MIDDLE AGED;

EID: 84865509465     PISSN: 03682781     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. AOKI, Y.: Bactericidal activity of arbekacin against methicillin- resistant Staphylococcus aureus. Comparison with that of vancomycin. Jpn. J. Antibiotics 47: 640-646, 1994
2. KONDO, S.; K. IINUMA, H. YAMAMOTO, et al.: Syntheses of 1-N- {(S)-4-amino-2-hydroxybutyryl}-kanamycin B and -3′, 4′- dideoxykanamycin B active against kanamycin-resistant bacteria. J. Antibiot. 26: 412-415, 1973
3. KIMURA, T.; K. SUNAKAWA, N. MATSUURA, et al.: Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates. Antimicrob. Agents Chemother. 48: 1159-1167, 2004
4. KOGA, K.; Y. KUSAWAKE, Y. ITO, et al.: Enhancing mechanism of Labrasol on intestinal membrane permeability of the hydrophilic drug gentamicin sulfate. Eur. J. Pharm. Biopharm. 64: 82-91, 2006
5. BLASER, J.; H. L. RIEDER & R. LÜTHY: Interface-area-to-volume ratio of interstitial fluid humans determined by pharmacokinetic analysis of netilmicin in small and large skin blisters. Antimicrob. Agents Chemother. 35: 837-839, 1991
6. DEE, T. H. & F. KOZIN: Gentamicin and tobramycin penetration into synovial fluid. Antimicrob. Agents Chemother. 12: 548-549, 1977
7. THYS, J. P.; E. SERRUVS-SCHOUTENS, P. ROCMANS, et al.: Amikacin concentrations in uninfected postthoracotomy pleural fluid and in serum after intravenous and intrapleural injection. Chest 85: 502-505, 1984
8. KOZAK, A. J.; D. N. GERDING, L. R. PETERSON, et al.: Gentamicin intravenous infusion rate: effect on interstitial fluid concentration. Antimicrob. Agents Chemother. 12: 606-608, 1977
9. CHISHOLM, G. D.; P. M. WATERWORTH, J. S. CALNAN, et al.: Concentration of antibacterial agents in interstitial tissue fluid. Br. Med. J. 10: 569-573, 1973
10. LORENTZEN, H.; F. KALLEHAVE, H. J. KOLMOS, et al.: Gentamicin concentrations in human subcutaneous tissue. Antimicrob. Agents Chemother. 40: 1785-1789, 1996
11. ROSIN, E.; S. EBERT, T. S. UPHOFF, et al.: Penetration of antibiotics into the surgical wound in a canine model. Antimicrob. Agents Chemother. 33: 700-704, 1989
12. SATO, R.; Y. TANIGAWARA, M. KAKU, et al.: Pharmacokinetic-pharmacodynamic relationship of arbekacin for treatment of patients infected with methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 50: 3763-3769, 2006
13. RODRIGUEZ-NORIEGA, E.; S. ESPARZA-AHUMADA, & R. MORFIN-OTERO: Comparison of the efficacy and safety of isepamicin and amikacin in the treatment of skin and skin structure infections. J. Chemother. 7: 155-160, 1995
14. CAMPOLI-RICHARDS, D. M.; S. CHAPLIN, R. H. SAYCE, et al.: Netilmicin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 38: 703-756, 1989
15. RYBAK, M. J.; B. J. ABATE, S. L. KANG, et al.: Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob. Agents Chemother. 43: 1549-1555, 1999
16. NICOLAU, D. P.; C. D. FREEMAN, P. P. BELLIVEAU, et al.: Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob. Agents Chemother. 39: 650-655, 1995
17. MEUNIER, F.; P. VAN DER AUWERA, H. SCHMITT, et al.: Pharmacokinetics of gentamicin after i.v. infusion or iv bolus. J. Antimicrob. Chemother. 19: 225-231, 1987
18. YANG, R. H.; X. Z. RONG, R. HUA, et al.: Pharmacokinetics of vancomycin and amikacin in the subeschar tissue fluid in patients with severe burn. Burns 35: 75-79, 2009
19. SEGAL, J. L.; S. R. BRUNNEMANN & I. M. ELTORAI: Pharmacokinetics of amikacin in serum and in tissue contiguous with pressure sores in humans with spinal cord injury. Antimicrob. Agents Chemother. 34: 1422-1428, 1990
20. TANIGAWARA, Y.; R. SATO, K. MORITA, et al.: Population pharmacokinetics of arbekacin in patients infected with methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 50: 3754-3762, 2006
21. KIRBY, J. T.; A. H. MUTNICK, R. N. JONES, et al.: Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (2000). Diagn. Microbiol. Infect. Dis. 43: 303-309, 2002
22. STEVENS, D. L.; A. L. BISNO, H. F. CHAMBERS, et al.: Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin. Infect. Dis. 41: 1373-1406, 2005
23. GOULD, F. K.; R. BRINDLE, P. R. CHADWICK, et al.: Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom. J. Antimicrob. Chemother. 63: 849-861, 2009
24. WEIGELT, J.; K. ITANI, D. STEVENS, et al.: Linezolid versus vancomycin in treatment of complicated skin and soft tissue infection. Antimicrob. Agents Chemother. 49: 2260-2266, 2005
25. WILSON, S. E.; J. S. SOLOMKIN, V. LE, et al.: A severity score for complicated skin and soft tissue infections derived from phase III studies of linezolid. Am. J. Surg. 185: 369-375, 2003